13F Holdings
中文EN

OCUL OCULAR THERAPEUTIX, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1393434 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-9.7%
TTM net income YoY-30.9%
TTM EPS YoY-0.7%
Revenue 3-yr CAGR-4.4%
Net income 3-yr CAGR—

Margins

Gross margin87.3%
Operating margin-680.9%
Net margin-648.6%
FCF margin-530.0%
EBITDA margin-667.4%

Returns

ROE-93.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.10x

Leverage & solvency

Liabilities / assets27.2%
Debt / equity0.00x
Current ratio9.12x
Interest coverage-30.59x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue27.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$51.95M$63.72M$58.44M$51.49M$43.52M
Cost of revenue$6.57M$5.63M$5.28M$4.54M$4.41M
Gross profit$45.38M$58.10M$53.16M$46.95M$39.12M
R&D expense$197.10M$127.64M$61.05M$53.46M$50.08M
SG&A expense$64.38M$60.65M$33.94M$32.22M$31.88M
Operating income-$270.02M-$171.78M-$82.38M-$78.65M-$78.04M
Interest expense$11.84M$13.58M$11.34M$7.02M$6.67M
Income tax$0$0$0$0$0
Net income-$265.94M-$193.51M-$80.74M-$71.04M-$6.55M
EBITDA-$265.69M-$168.00M-$79.40M-$76.55M-$75.62M
EPS (basic)-1.42-1.22-1.01-0.92-0.09
EPS (diluted)-1.42-1.22-1.02-0.97-0.98
Weighted avg. shares (diluted)187.24M158.27M85.60M82.64M82.16M
Balance sheet
Cash & equivalents$737.06M$393.72M$195.81M$104.06M$165.93M
Receivables$30.65M$32.39M$26.18M$21.32M$21.14M
Inventory$3.56M$3.04M$2.31M$1.97M$1.25M
Current assets$782.13M$440.99M$232.24M$129.63M$191.30M
PP&E, net$19.68M$9.39M$11.74M$9.86M$6.96M
Total assets$808.06M$457.94M$252.06M$149.29M$204.89M
Current liabilities$50.81M$41.35M$34.90M$31.39M$26.34M
Total liabilities$153.75M$142.59M$160.93M$113.91M$116.89M
Shareholders' equity$654.31M$315.34M$91.13M$35.38M$88.00M
Shares outstanding215.93M157.75M114.96M77.20M76.73M
Cash flow statement
Operating cash flow-$204.88M-$134.68M-$70.23M-$59.60M-$65.55M
Capital expenditure$12.01M$1.29M$6.09M$3.71M$1.19M
Free cash flow-$216.89M-$135.97M-$76.32M-$63.32M-$66.74M
Investing cash flow-$11.88M-$1.29M-$6.09M-$3.71M-$1.19M
Financing cash flow$561.72M$332.11M$169.83M$1.45M$2.85M
Depreciation & amortization$4.32M$3.79M$2.98M$2.11M$2.42M
Stock-based compensation$43.18M$33.11M$17.82M$16.96M$14.98M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.